67/100Visit OpenLoop
Ranked #3 of 10
OpenLoop
Enterprise white-label virtual care infrastructure.
Last verified 2026-10-31
Score breakdown
- Team and clinical leadership12 / 15
- Risk to your business3 / 15
- Product range15 / 15
- Ongoing cost4 / 10
- Brand ownership8 / 10
- Compliance transparency6 / 10
- Partner tools10 / 10
- Speed to launch3 / 5
- Track record6 / 10
Total: 67 / 100. How we score
Overview
Enterprise white-label virtual care infrastructure.
Best for: Digital health companies and large brands, including insurance-billed programs
Who's behind it
- Team
- Established, venture-backed company ($8M and $15M Series A rounds) with a large in-house clinician network.
- Clinical leadership
- Its own 50-state clinician network of thousands of licensed clinicians.
Business risk
Pricing not published. Two competitor comparison pages report an implementation fee of $6,000 to $9,000, and a 12-month initial term.
Products, pricing and compliance
- Products
- Peptides, GLP-1s, Hormone therapy, Lab testing, Dermatology, Sexual health, Mental health, Urgent care
- Named products
- GLP-1s, Sermorelin, NAD+, B-12; limited peptides
- States
- All 50 states
- Pharmacy
- Nationwide 503A and 503B pharmacies
- Brand ownership
- Your brand ("We build it. You brand it.")
- Pricing
- Not published. Competitor-published figures: $6,000 to $9,000 implementation, $1,500/mo, 12-month initial term.
- Starting price
- Not published
- Estimated year-one cost
- About $24,000 to $27,000
- Compliance
- LegitScript certified (2023), SOC 2 Type 1 (2024), NCQA credentialing certification
- Reviews
- Trustpilot 4.8, as reported by OpenLoop
Launch time and partner tools
- Launch time
- 1 to 2 weeks for most programs, per OpenLoop
- Partner tools
- White-label website builder, intake dashboard, patient portal, EHR, reporting, API, 600+ insurance plans
Pros and cons
Pros
- One of the largest and longest-running platforms
- Widest catalog, including insurance billing
- Formal credentials: LegitScript, SOC 2, NCQA
Cons
- Enterprise-style terms: heavy onboarding fees, 12-month contract
- Reported a January 2026 data breach affecting up to 716,000 people
- Built for enterprise customers, not independent studios
Notable news
HIPAA Journal reported a January 2026 data breach affecting up to 716,000 people. Named with Triad Rx in a pending class action over compounded oral tirzepatide (allegations, unresolved).
Sources
- OpenLoop program overview
- OpenLoop: LegitScript certification
- OpenLoop: SOC 2 Type 1
- OpenLoop: $15M Series A
- HIPAA Journal: OpenLoop data breach
- Chimicles: oral tirzepatide class action
- Cuvo vs OpenLoop Competitor-published
- Heally vs OpenLoop Competitor-published
Last verified 2026-10-31. Spot an error? Email corrections@addrx.com.